NNVC NanoViricides Inc
Company Analysis
Latest News
🟢 NanoViricides is trading 12% up today after positive NV-387 juvenile-mouse safety results
NanoViricides is trading 12.31% higher at $1.46 after announcing positive juvenile-mouse safety results for NV-387 on October 20, 2026. - The candidate was...
NanoViricides Shares Jump 8% on Positive Mouse Study, but Can Preclinical Data Justify a Path to Real Revenue?
Shares of NanoViricides (NNVC) surged 8.5% to $1.41 on October 20 after the clinical-stage biotech announced that its antiviral drug candidate, NV-387, showed...
🟢 NanoViricides is trading 8.5% up on October 20, 2026, after NV-387 showed favorable juvenile safety results
NanoViricides is trading at $1.41, up 8.46%, alongside its October 20, 2026 announcement that NV-387 showed favorable safety and tolerability in a juvenile...
🔴 NanoViricides is trading 5% down with no clear catalyst
NanoViricides is trading at $1.31, down 5.07%, with no company-specific explanation for the October 19 decline in available reporting. - Its latest listed...
🟢 NanoViricides rises 6.1% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 NanoViricides is trading 6% up in pre-market; Ebola trial update's role is unconfirmed
NanoViricides is trading at $1.40, up 5.95% in pre-market, with its Ebola trial update as relevant but unconfirmed context. - On October 13, 2026,...
🟢 NanoViricides is trading 5.3% up in after-hours trading alongside Ebola trial enrollment update
NanoViricides is trading at $1.40, up 5.26% in after-hours trading; its Ebola trial update is possible context, not a confirmed cause. - On October 13, 2026,...
🟢 NanoViricides rises 5.3% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 NanoViricides is trading 5.6% down; cause remains unclear
NanoViricides is trading 5.6% lower at $1.36 on October 8, 2026, with no clear company-specific catalyst identified. - Shares pulled back from the October 7...
🟢 NanoViricides is trading 5% up today with no clear catalyst identified
NanoViricides is trading 5.00% higher at $1.47 on October 7, 2026, with no clear company-specific catalyst identified. - The company announced a presentation...
🔴 NanoViricides is trading 5.2% down on October 6, 2026 with XBI down 2.50%
NanoViricides is trading at $1.37, a change of -5.19%, with biotech-sector pressure the clearest available context. - XBI fell 2.50% in the session, while...
NanoViricides Jumps 10% on Ebola Trial Update, but Can a Phase IIA Study Justify the Hype?
Shares of NanoViricides (NNVC) surged 10.5% to $1.42 on October 5 after the company confirmed its NV-387 Phase IIA clinical trial for Ebola is proceeding as...
🟢 NanoViricides is trading 11% up today amid an NV-387 Ebola trial update
NanoViricides is trading at $1.42, up 10.55%, alongside an update that its NV-387 Phase II Ebola trial is proceeding as designed. - On October 5, 2026, the...
🟢 NanoViricides soars 7.1% on positive NV-387 Ebola trial update
NanoViricides surged 7.1% to $1.37 today after providing a positive update on its NV-387 Phase IIA Ebola trial. - The company announced on October 5, 2026,...
🟢 NanoViricides is trading 7% up amid Ebola trial update
NanoViricides is trading 7.03% higher at $1.37, with its October 5 Phase II Ebola trial update a possible catalyst; a direct link to the move is unconfirmed. -...
NanoViricides Inc Q2 2026 Earnings Preview: What Analysts Expect on October 05, 2026
NanoViricides is expected to report a consensus EPS of -$0.11 on zero revenue for the quarter ending June 30, 2026, with the current $1.30 stock price trading...
🟢 NanoViricides is trading 7.9% up in pre-market with no October 2 company-specific catalyst identified
NanoViricides is trading 7.9% higher in pre-market at $1.36, compared with the October 1 close of $1.26; no new company-specific announcement dated October 2...
NanoViricides Starts Phase II Ebola Trial, Says More Funding Is Needed
NanoViricides, Inc. announced that patients have been enrolled and dosed in its Phase II clinical trial of NV-387 oral gummies for Ebola in the Democratic...
🟢 NanoViricides is trading 7.7% up in pre-market with no clear catalyst identified
NanoViricides is trading at $1.40, up +7.69% in pre-market, with no clear catalyst identified for the September 30 move. - The company’s fiscal 2026 annual...
🔴 NanoViricides is trading 10.3% down
NanoViricides is trading 10.3% down at $1.34 on September 29, 2026, with no clearly identified catalyst for the intraday decline. - The company announced...